Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
186 hedge funds and large institutions have $1.24B invested in Clovis Oncology, Inc. in 2019 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 62 increasing their positions, 49 reducing their positions, and 18 closing their positions.
122% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 18
30% more capital invested
Capital invested by funds: $953M → $1.24B (+$285M)
27% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 49
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
21% more call options, than puts
Call options by funds: $50.7M | Put options by funds: $41.8M
13% more funds holding
Funds holding: 165 → 186 (+21)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$35.1M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$20.2M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$12.6M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$12.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$73.6M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$32.6M |
| 3 |
PC
PointState Capital
New York
|
-$18.7M |
| 4 |
SC
Samlyn Capital
New York
|
-$15.9M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15.1M |
CLVS Hedge Fund Activity: Q1 2019 in Review
186 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2019, worth a combined $1.24B — up 30% from $953M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new CLVS positions and 18 closed out — a net gain of 22 holders — while 62 added to existing stakes and 49 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $35.1M. The largest seller was Armistice Capital, cutting an estimated $73.6M.
- 186 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2019, up from 165 in Q4 2018.
- Funds reported $1.24B of Clovis Oncology, Inc. stock for Q1 2019, up 30% quarter-over-quarter.
- 40 funds opened new Clovis Oncology, Inc. positions in Q1 2019 and 18 closed out, a net change of +22 holders.
- The largest Clovis Oncology, Inc. buyer in Q1 2019 was HealthCor Management, an estimated $35.1M added.
- The largest Clovis Oncology, Inc. seller in Q1 2019 was Armistice Capital, an estimated $73.6M sold.
Based on aggregated 13F filings for Q1 2019.